Company: SHPH
Filing Date: 2025-11-18
Form Type: S-1
Source: 0001493152-25-024089
Chunk: 6

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-11-18
Form: S-1
Chunk 6
---
 of the pre-funded warrant issued under the Purchase Agreement.

| 5 |

<div align='center'>RISK FACTORS</div>

An investment in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties discussed below, as well as those under the heading “Risk Factors” contained in our most recent annual report on Form 10-K filed with the SEC, and as incorporated by reference in this prospectus, as the same may be amended, supplemented or superseded by the risks and uncertainties described under similar headings in the other documents that are filed by us after the date hereof and incorporated by reference into this prospectus. Please also read carefully the section below titled “Cautionary Note Regarding Forward-Looking Statements.”

The sale of a substantial amount of our common stock, including resale of the shares of common stock by the selling stockholder in the public market, could adversely affect the market price of our common stock.

We are registering for resale 625,156 shares of common stock issuable upon the exercise of a pre-funded warrant held by the selling stockholder. Sales of substantial amounts of our common stock in the public market, or the perception that such sales might occur, could adversely affect the market price of our common stock. We cannot predict if and when the selling stockholder may sell such shares in the public market.

Future acquisitions may have a material adverse effect on our ability to manage our business and our results of operations and financial condition.

We may acquire assets, businesses, technologies, services, or products which are complementary to our operations. Future acquisitions, such as the currently contemplated asset acquisition pursuant to the binding term sheet with 1542770 BC Ltd. (“Molecule”) dated October 20, 2025, pursuant to which the Company or its affiliate will purchase from Molecule substantially all of Molecule’s assets and liabilities (the “Asset Purchase”), may expose us to potential risks, including risks associated with our ability to enter into material agreements to complete the Asset Purchase, not receiving the intended benefits of the Asset Purchase, our ability to close the Asset Purchase on the expected timeline or at all, the diversion of resources and management attention from our existing business and technology, the costs and expenses incurred in connection with such acquisitions, or the potential loss of or harm to relationships with suppliers, employees, and customers resulting from our integration of a new asset class. If any of these risks were to occur, our operations could be materially and adversely affected.

<div align='